

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:167404 CAPLUS
DOCUMENT NUMBER: 144:211757
TITLE: Lipoic acid concentrate for
reducing diets.
INVENTOR(S): Behnam, Dariush
PATENT ASSIGNEE(S): Aquanova German Solubilisate Technologies (AGT)
G.m.b.H., Germany
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018301	A1	20060223	WO 2005-EP8940	20050818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1781119	A1	20070509	EP 2005-776037	20050818
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2007513994	T	20070531	JP 2006-544471	20050818
CN 101001543	A	20070718	CN 2005-80025712	20050818
US 20060287384	A1	20061221	US 2006-572918	20060321
US 20070043106	A1	20070222	US 2006-392957	20060330
PRIORITY APPLN. INFO.:			DE 2004-102004040178A	20040818
			WO 2005-EP8940	W 20050818

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RECORDS ARE MAINTAINED IN THE RE FORM

TI Lipoic acid concentrate for reducing diets.

AB The invention relates to an anhydrous concentrate consisting of ubiquinone Q10, a medium-chain triglyceride or triglyceride mixture, .alpha.-lipoic acid and/or the derivs. thereof, and at least one emulsifier authorized for food or medicaments and having an HLB value of between 9 and 19.

ST reducing diet appetite suppressant lipoate ubiquinone MCT

IT Glycerides, biological studies
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-10; lipoic acid concentrate for reducing diets)

IT Drug delivery systems
(capsules; lipoic acid concentrate for reducing diets)

IT Food
(dietetic; lipoic acid concentrate for reducing diets)

IT Appetite depressants
Beverages
Dairy products
Emulsifying agents

Food additives
 Honey
 (lipoic acid concentrate for reducing diets)
 IT Glycerides, biological studies
 Safflower oil
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (lipoic acid concentrate for reducing diets)
 IT Glycerides, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (medium-chain; lipoic acid concentrate for reducing diets)
 IT Diet
 (reducing; lipoic acid concentrate for reducing diets)
 IT Fats and Glyceridic oils, biological studies
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vegetable; lipoic acid concentrate for reducing diets)
 IT 124-07-2, Caprylic acid, biological studies 303-98-0, Ubiquinone
 Q10 334-48-5, Capric acid 462-20-4, Dihydrolipoic acid 1200-22-2,
 α -Lipoic acid 3884-47-7,
 Dihydrolipoamide 9005-64-5, Polysorbate 20 9005-65-6,
 Polysorbate 80
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (lipoic acid concentrate for reducing diets)

=> D ibib hit 17 2-3

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:171651 CAPLUS
 DOCUMENT NUMBER: 136:205457
 TITLE: Palatable oral coenzyme Q liquid
 INVENTOR(S): Chopra, Raj K.
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017879	A1	20020307	WO 2001-US25755	20010817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 6441050	B1	20020827	US 2000-650487	20000829
CA 2417089	A1	20020307	CA 2001-2417089	20010817
AU 2001083426	A5	20020313	AU 2001-83426	20010817
EP 1313447	A1	20030528	EP 2001-962230	20010817
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:

US 2000-650487

A 20000829

WO 2001-US25755

W 20010817

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The present invention relates to a composition in pharmaceutical dosage form of coenzyme Q or ubiquinol which can be administered to children in a oral dosage form as a pleasant-tasting liquid. The dosage form comprises an effective amount of coenzyme Q or ubiquinol ranging from about 0.05 to about 10, more preferably about 1 to about 7.5 by weight of the composition in combination with a minor amount of a polysorbate surfactant such as a Tween surfactant, most preferably, polysorbate 80, a major amount of a vegetable oil or triglyceride, in further combination with an amount of phospholipid such as hydroxylated lecithin effective to maintain ubiquinone/ubiquinol in hydrosol. form and to substantially enhance the palatability of ubiquinone or ubiquinol in combination with a sweetener solution as well as an amount of water preferably ranging from about 5 to about 45 by weight

IT Alditols

Flavonoids

Minerals, biological studies

Phosphatidic acids

Phosphatidylcholines, biological studies

Phosphatidylethanolamines, biological studies

Phosphatidylinositols

Phosphatidylserines

Phospholipids, biological studies

Sphingomyelins

Tocopherols

 Ubiquinones

Vitamins

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

 (palatable oral coenzyme Q liquid)

IT 56-81-5, Glycerol, biological studies 57-48-7, Fructose, biological studies 57-50-1, Sucrose, biological studies 57-55-6, Propylene glycol, biological studies 59-02-9, α -Tocopherol 64-17-5, Ethanol, biological studies 68-26-8, Retinol 69-79-4, Maltose 81-07-2, Saccharin 83-88-5, Riboflavin, biological studies 100-88-9, Cyclamate 116-31-4, Retinal 127-47-9, Retinyl acetate 137-66-6, Ascorbyl palmitate 302-79-4, Retinoic acid 432-70-2, α -Carotene 502-65-8, Lycopene 541-15-1, L-Carnitine 1200-22-2, α -Lipoic acid 3040-38-8, Acetyl-L-carnitine 4539-70-2, Distearoylphosphatidylcholine 7235-40-7, β -Carotene 9005-65-6, Tween 80 18656-38-7, Dimyristoylphosphatidylcholine 20064-19-1, Propionyl-L-carnitine 22839-47-0, Aspartame 56038-13-2, Sucralose 61361-72-6, Dimyristoylphosphatidylglycerol

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

 (palatable oral coenzyme Q liquid)

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:741547 CAPLUS

DOCUMENT NUMBER: 135:293963

TITLE: Oral pharmaceuticals containing coenzyme Q with high dissolution qualities

INVENTOR(S): Chopra, Raj K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 11 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6300377	B1	20011009	US 2001-790783	20010222
CA 2432020	A1	20020906	CA 2002-2432020	20020220
WO 2002067864	A2	20020906	WO 2002-US5970	20020220
WO 2002067864	A3	20021219		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002252132	A1	20020912	AU 2002-252132	20020220
EP 1505958	A2	20050216	EP 2002-721189	20020220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2001-790783	A 20010222
			WO 2002-US5970	W 20020220

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB The present invention relates to a composition in liquid dosage form of coenzyme

Q or ubiquinone which can be formulated into cosmetic, dietary supplement or pharmaceutical dosage form for administration to patients. The dosage form comprises an effective amount of coenzyme Q or ubiquinone ranging from about 0.05 to about 15, more preferably about 1 to about 10.0 by weight of the composition in combination with a polysorbate surfactant such as a Tween®, surfactant, a vegetable oil or triglyceride, in further combination with a glyceryl ester in amts. effective to produce a liquid dosage form. Optional additives include a phospholipid such as hydroxylated lecithin, among others such as tocopherols or tocopherol esters effective to solubilize the ubiquinone in combination as well as other bioactive agents. Compns. according to the present invention avoid the inclusion of a polyhydric alc. solvent in solubilizing amts. A liquid dosage form contained coenzyme Q10 7, Tween 80 (Polysorbate 80) 38, Tributyrin (Glyceryl tributyrate) 19, medium chain triglycerides 19, and vitamin E alc. (or acetate) 17%. The formulation resulted in 100% dissoln.

IT Carotenes, biological studies

Flavonoids

Glycerides, biological studies

Phosphatidic acids

Phosphatidylcholines, biological studies

Phosphatidylethanolamines, biological studies

Phosphatidylglycerols

Phosphatidylinositols

Phosphatidylserines

Phospholipids, biological studies

Proanthocyanidins

Sphingomyelins

Ubiquinones

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral pharmaceuticals containing coenzyme Q with high dissoln. qualities)

IT 50-81-7, vitamin c, biological studies 50-81-7D, L-Ascorbic acid, esters
52-90-4, L-Cysteine, biological studies 53-57-6, NADPH 56-81-5D,
Glycerol, esters 58-68-4, NADH 59-02-9, α -Tocopherol 60-01-5,
(Glyceryl tributyrate) 68-26-8, Retinol 70-18-8, Glutathione,
biological studies 83-88-5, Riboflavin, biological studies 98-92-0,
Niacinamide 102-76-1, Glyceryl triacetate 116-31-4, Retinal
127-40-2, Lutein 127-47-9, Retinol acetate 137-66-6, Ascorbyl
palmitate 144-68-3, Zeaxanthin 302-79-4, Retinoic acid 302-79-4D,
Retinoic acid, esters 302-79-4D, Retinoic acid), reduced 432-70-2,
 α -Carotene 472-61-7, Astaxanthin 501-36-0, Resveratrol
502-65-8, Lycopene 541-15-1, L-Carnitine 616-91-1, N-Acetyl cysteine
816-94-4, Distearylphosphatidylcholine 1200-22-2D, α -
Lipoic acid, reduced 1406-18-4, vitamin E 3040-38-8,
Acetyl L-carnitine 6829-55-6, Tocotrienol 7235-40-7, β -Carotene
7439-95-4, Magnesium, biological studies 7439-96-5, Manganese,
biological studies 7440-66-6, Zinc, biological studies 7782-49-2,
Selenium, biological studies 9005-65-6, Tween 80 11103-57-4, vitamin A
18194-24-6, Dimyristoylphosphatidylcholine 20064-19-1, Propionyl
L-carnitine 61361-72-6, Dimyristoylphosphatidylglycerol 73573-88-3,
Mevastatin 75330-75-5, Lovastatin 79902-63-9, Simvastatin
81093-37-0, Pravastatin 93957-54-1, Fluvastatin 93957-55-2,
Fluindostatin 134523-00-5, Atorvastatin 145599-86-6, Cerivastatin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral pharmaceuticals containing coenzyme Q with high dissoln. qualities)

=> d his

(FILE 'HOME' ENTERED AT 11:15:04 ON 19 AUG 2008)

FILE 'CAPLUS' ENTERED AT 11:15:17 ON 19 AUG 2008
E LIPOIC ACID+ALL/CT
E (LIPOIC ACID OR "A-LIPOIC ACID")
E UBIQUINONE
E LIPOIC ACID
E A-LIPOIC ACID
SET EXPAND CONTINUOUS PERM
E UBIQUINONE
E LIPOIC ACIDS
E LIPOIC ACID+ALL/CT
E DIHYDROLIPOIC ACID
E LIPOICACID OR "A-LIPOICACID" OR DIHYDROLIPOICACID
E DIHYDROLIPOICACID
E DIHYDROLIPOICACID OR LIPOICACID OR "ALPHA"-LIPOICACID
L1 10399 S E15
L2 4 S E53 OR E66
E LIPOIC ACID+ALL/CT
L3 4848 S (LIPOIC ACID OR "A-LIPOIC ACID") OR "1,2-DITHIOLANE-3-P
L4 31 S L1 (S) L3
E POLYSORBATE
E TRIGLYCERIDE
L5 5661 S E93
E E105
L6 75662 S E105
L7 3 S L1 AND L3 AND L5 AND L6